Literature DB >> 2645493

Preoperative assessment of parotid masses: a comparative evaluation of radiologic techniques to histopathologic diagnosis.

M N Byrne1, J G Spector, C F Garvin, M H Gado.   

Abstract

A double-blind, retrospective analysis of 110 sequentially operated parotid masses compared the usefulness of preoperative radiologic evaluation to histopathologic diagnosis. The radiologic assessment included 25 sialograms, 162 computed tomography scans, and 10 nuclear magnetic resonance images. The diagnosis is influenced by the following four parameters of computed tomography: tumor borders, density, homogeneity, and enhancement. Well-defined borders, a homogeneous appearance, and high density strongly favor the diagnosis of a benign tumor or a low-grade malignancy (96.7%). Ill-defined tumor borders, heterogeneity, and high density indicate mainly a high-grade or recurrent malignancy (68.8%). Ill-defined borders, a heterogeneous appearance, and mixed density identify a lymphoepithelial lesion, lymphangioma, or sialoadenitis (100%). Sialography is cost effective in the evaluation of lymphoepithelial lesions. Computed tomography sialography offers no advantages over computed tomography with intravenous contrast. High-resolution computed tomography with intravenous contrast is highly sensitive for tumor detection (97%). Magnetic resonance imaging is complementary or superior to computed tomography (100%).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645493     DOI: 10.1288/00005537-198903000-00009

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  [On the diagnosis and treatment of parotid gland tumors. Results of a nationwide survey of ENT hospitals in Germany].

Authors:  S F Preuss; O Guntinas-Lichius
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

2.  Diagnosis and management of lymphoepithelial lesion of the parotid gland.

Authors:  Qin Ma; Hong Song
Journal:  Rheumatol Int       Date:  2010-11-11       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.